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Forced expiratory volume in one second (FEV1)
was described by Tiffeneau and Pinelli, working in
Paris in 1947, and in 1951 by Gaensler in the USA.(1-
2) Maximal voluntary ventilation (MVV) had previously
been described, and reduced MVV in individuals
suffering from lung dissease had been correlated with
the degree of dyspnea. Tiffenau and Gaensler
observed that the pertinent portion of the forced
expiration maneuver was the initial part since, in the
MVV maneuver, the length of each expiration was
typically less than one second. Gaensler correlated
MVV with various forced expiratory volumes and
found the best correlation to be with FEV1.
(2)
Since FEV1 is a highly reproducible parameter that
correlates with chronic obstructive pulmonary disease
(COPD) prognosis, it has, in recent decades, come to
be considered the most relevant functional data to
be obtained in tests of pulmonary function.(3)
In a study based on the coefficient of variation
of diverse functional parameters, including data
obtained through plethysmography, Light et al.
concluded that FEV1 was still the most important
functional parameter in the evaluation of
bronchodilator response.(4)
In 1988, Guyatt et al. demonstrated that one-
third of all COPD patients responded to a
bronchodilator in the pulmonary function laboratory,
whereas two-thirds responded in multiple spirometric
tests, and that there was no correlation between acute
and long-term bronchodilator response.(5) Recent
studies have confirmed these findings, including
response to the same class of bronchodilators, among
them the long-acting bronchodilators.(6-8) In all of
these studies, FEV1 was used to evaluate the response.
In the last 25 years, various studies have
demonstrated that exercise tolerance, as measured
using a walk test, improves after bronchodilator use.
Surprisingly, no correlation has been found between
increased distance walked and variations in FEV1.
(9)
Studies conducted in the 1980s demonstrated that
improved exercise tolerance after bronchodilator use
correlated better with changes in slow vital capacity
(SVC) than with changes in FEV1.
(9)
In the 1990s, it became clear that, in patients
with COPD, dyspnea upon exertion correlated better
with air trapping, which is accentuated during
exercise.(10) The realization that significant
improvement in symptoms, exercise tolerance and
quality of life could occur when there was little
variation in FEV1 resulted in a search for better
methods of evaluation. Studies conducted in recent
years clearly demonstrate that the symptomatic benefit
in COPD patients is attributable to a pharmacological
reduction in lung volume.(9,11-12)
In COPD, increased end-expiratory volume is
reflected as a drop in inspiratory capacity (IC).
Therefore, increases in IC after bronchodilator use
are associated with better exercise tolerance.(9-12)
The study conducted by Tavares et al.(13) and
presented in this issue of the journal shows that 90%
of patients with COPD responded in one or more
functional parameters after bronchodilator use,
although FEV1 detected only 31% of the responses.
Forced vital capacity (FVC) was the parameter that
varied most frequently, followed by residual volume,
specific airway conductance and SVC.
Various findings explain the poor predictive value
of FEV1 for improved exercise tolerance and reduced
dyspnea. The FEV1 parameter does not provide
information regarding the degree of limitation in
expiratory flow, as seen in the expiratory flow-volume
curve, or regarding the degree of air trapping. All of
these parameters are relevant in relation to the
dyspnea and limited exercise tolerance seen in COPD,
and each can vary greatly for a given value of FEV1.
(14)
The functional response to a bronchodilator can
be classified as either a response in flow or a response
in volume. In COPD, volume responses are generally
observed more frequently in patients presenting a
greater degree of obstruction, which, ironically,
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preserves the efficacy of bronchodilators in many
advanced cases of the disease.(15)
The value of FEV1 can be a parameter either of
flow response or of volume response. In many
patients, variations in FEV1 after bronchodilator use
simply reflect recruitment of lung volume, i.e. the
FEV1/FVC ratio does not change, demonstrating
reduced air trapping caused by the concomitant
increase in FVC. In the Tavares et al. study,(13) the
significantly higher rate of response in SVC and FVC
by patients in the group that presented significantly
elevated FEV1 is evidence of such volume recruitment.
As recognized by the authors, the use of multiple
tests aimed at detection of a single abnormality can
lead to false-positive results. However, analyzing
bronchodilator response in various parameters can
express different physiological phenomena. A
reduction in air trapping, with the consequent
reduction in thoracic gas volume, introduces some
difficulties in the interpretation of airway resistance
and airway conductance. A reduction in lung volume
resulting from bronchodilator use causes an increase
in airway resistance, which is reduced through the
use of medication. Therefore, it is not surprising that
tests of airway resistance present low sensitivity. In
addition, adjusting increases in airway conductance
for lung volume, which would express airway dilation
under isovolumic conditions, appears interesting.
However, the 50% increase in relation to baseline
values, held as significant, could be less so because
many patients with airflow obstruction present
baseline values below 0.05 L/cmH2O/s. Therefore,
small absolute variations, within the error of
measurement, can result in considerable percentage
variations.
In the study, the post-bronchodilator variations
adopted for SVC, FVC and IC correlated with relevant
improvement in exercise tolerance.(9) No such cutoff
point was established for RV, although the criterion
adopted (20% increase over predicted) seems
reasonable.(16)
In several recent studies, it was demonstrated that
long-acting bronchodilators reduce air trapping,
minimize dyspnea and improve quality of life for
individuals with COPD.(17-19) Compared to salmeterol,
formoterol results in a more rapid reduction in air
trapping in COPD patients, which explains the fact
that many such patients prefer formoterol.(19)
Despite the fact that, in COPD, bronchodilators
can increase exercise tolerance by reducing air
trapping, not all patients respond. In addition, a lack
of response to a certain class of drugs does not
preclude the possibility of a response to a different
category of bronchodilator. The limited exercise
tolerance seen in COPD is multifactorial (including
diverse factors other than ventilatory limitation).(20)
The role of FEV1 in predicting the long-term
response of a COPD patient to a bronchodilator is
limited. However, there have been few studies utilizing
lung volumes, including the measurement of RV and
IC, to that end. If positive, such studies could establish
a relevant, previously unknown, role for pulmonary
function tests in COPD patients and could allow
physicians to prescribe, with greater confidence and
no longer in an empirical fashion, medications that
are, in some cases, quite costly.
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